Aquestive Therapeutics Inc is trading 5.6% up today at $4.21, rebounding from recent weakness and extending this week’s modest gains amid a broader risk-on market tone.
- The move aligns with major U.S. indices rising more than 1% on June 11, 2026, despite an absence of fresh company-specific headlines or filings.
- Investor attention remains focused on the company's earlier Q1 2026 earnings beat and ongoing developments regarding Anaphylm-related FDA progress and litigation.